The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
ANVISA issues CGMP to Concord Biotech’s Unit I
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
This agreement paves the way for the introduction of YESAFILI into the Canadian market
PLI scheme envisages manufacturing of 41 Bulk Drugs with a total outlay of Rs. 6,940 cr. during the tenure of the scheme from 2020-21 to 2029-30
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Global Initiative on Digital Health (GIDH) was launched by the WHO and the Government of India during the G20 Health Working Group meeting in Gandhinagar last year
Subscribe To Our Newsletter & Stay Updated
